Legal & General Group PLC Immunome Inc. Transaction History

Legal & General Group PLC

$431 Billion
Q3 2025

A detailed history of Legal & General Group PLC transactions in Immunome Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 81,073 shares of IMNM stock, worth $1.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

81,073

Previous 63,029 28.63%

Holding current value

$1.39 Million

Previous $586,000 60.24%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$8.4 - $11.59 $151,569 - $209,129	18,044 Added 28.63%	81,073 $939,000
Q2 2025 Aug 12, 2025	BUY	$5.56 - $9.79 $2,924 - $5,149	526 Added 0.84%	63,029 $586,000
Q1 2025 May 15, 2025	BUY	$6.73 - $11.83 $138,032 - $242,633	20,510 Added 48.84%	62,503 $420,000
Q4 2024 Feb 13, 2025	SELL	$9.11 - $14.53 $80,131 - $127,805	-8,796 Reduced 17.32%	41,993 $430,000
Q3 2024 Feb 28, 2025	BUY	$11.7 - $16.51 $1,053 - $1,485	90 Added 0.21%	42,083 $615,000

Q3 2024 Nov 14, 2024	BUY	$11.7 - $16.51 $2,597 - $3,665	222 Added 0.44%	50,789 $742,000
Q2 2024 May 29, 2025	BUY	$11.54 - $22.11 $128,474 - $246,150	11,133 Added 36.23%	41,861 $506,000
Q2 2024 Aug 14, 2024	BUY	$11.54 - $22.11 $228,942 - $438,640	19,839 Added 64.56%	50,567 $611,000
Q1 2024 May 29, 2025	SELL	$11.01 - $27.34 $349,842 - $868,728	-31,775 Reduced 50.84%	30,728 $758,000
Q1 2024 May 14, 2024	BUY	$11.01 - $27.34 $338,315 - $840,103	30,728 New	30,728 $758,000
Q2 2021 Aug 12, 2021	SELL	$16.33 - $32.33 $3,380 - $6,692	-207 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$9.56 - $43.24 $1,978 - $8,950	207 New	207 $7,000

Others Institutions Holding IMNM

# of Institutions

167

Shares Held

71.5M

Call Options Held

325K

Put Options Held

4.31M

View Full List

About Immunome Inc.

Ticker IMNM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,127,400
Market Cap $208M
Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...

More about IMNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Immunome Inc. Transaction History